Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
66.67
+10.67 (19.05%)
Feb 11, 2026, 2:18 PM EST - Market open
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.79M in the quarter ending September 30, 2025, a decrease of -51.13%. This brings the company's revenue in the last twelve months to $62.60M, down -32.79% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$62.60M
Revenue Growth
-32.79%
P/S Ratio
13.67
Revenue / Employee
$1,026,230
Employees
61
Market Cap
1.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| Iovance Biotherapeutics | 250.43M |
| Geron | 183.40M |
| Phathom Pharmaceuticals | 147.19M |
| UroGen Pharma | 96.52M |
| Vir Biotechnology | 16.86M |
| Nanobiotix | 11.93M |
NKTR News
- 6 hours ago - Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga
- 21 hours ago - Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript - Seeking Alpha
- 22 hours ago - Nektar Therapeutics Announces Proposed Public Offering - PRNewsWire
- 1 day ago - New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing - PRNewsWire
- 1 day ago - Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 - PRNewsWire
- 11 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 26 days ago - Nektar.io Introduces DIRT: Materials Management for the Construction Industry - Newsfile Corp
- 7 weeks ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha